RxDoctor Payments DataLook up a doctor →

Lance Sloan, MD

Endocrinology, Diabetes & Metabolism · Lufkin, TXNPI 1588665228

Payments from drug & device makers

$3,660,515in general payments, 2019–2025

Across 3,000 payments — averaging $1220.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim Pharma GmbH & Co.kg$560K
  • Boehringer Ingelheim International GmbH$522K
  • AstraZeneca$520K
  • Lilly USA, LLC$367K
  • Boehringer Ingelheim$266K
  • Eli Lilly$249K
  • plus $1.2M from 54 others
$31,871in research payments, 2019–2025

Across 40 payments — averaging $796.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$18K
  • Sanofi US Services Inc.$8K
  • Corcept Therapeutics$3K
  • Novo Nordisk AS$2K
  • Sanofi-aventis U.S. LLC$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim Pharma GmbH & Co.kg39$560,481
Boehringer Ingelheim International GmbH69$521,821
AstraZeneca(2 entities)614$519,645
Lilly USA, LLC526$366,697
Boehringer Ingelheim243$265,639
Eli Lilly56$249,431
Amgen(2 entities)84$196,097
Corcept Therapeutics201$192,363
GSK82$184,654
Johnson & Johnson155$134,122
Merck81$79,724
Sanofi-aventis U.S. LLC46$63,648
Janssen Research & Development, LLC11$63,271
Sanofi US Services Inc.6$56,911
Pfizer56$54,422
Bayer81$33,401
Novo Nordisk196$28,090
Novo Nordisk AS60$15,151
Abbott37$12,766
Janssen Scientific Affairs, LLC18$12,696
Rockwell Medical, Inc.16$11,736
Ascendis Pharma Endocrinology Inc13$8,265
Travere Therapeutics, Inc.42$6,302
Gilead16$4,571
Idorsia Pharmaceuticals US Inc3$4,201
Madrigal Pharmaceuticals9$4,046
Boehringer Ingelheim Limited4$2,058
AbbVie6$1,245
Amarin Pharma, Inc.42$897
Xeris Pharmaceuticals, Inc.27$783
Novartis19$708
Medtronic(2 entities)14$609
Dexcom, Inc.15$607
Radius Health, Inc.17$324
Lexicon Pharmaceuticals, Inc.3$303
Insulet Corporation12$255
Ionis Pharmaceuticals, Inc.2$242
Esperion Therapeutics, Inc.6$202
Medicure Pharma Inc.1$199
Calliditas Therapeutics US Inc.9$185
Scpharmaceuticals Inc.2$146
Otsuka Pharmaceutical Development & Commercialization, Inc.1$123
Mylan Inc.1$120
Endo Pharmaceuticals Inc.5$80
Recordati_rare_diseases_inc.3$76
Tandem Diabetes Care, Inc.4$72
Ardelyx, Inc.1$71
Genentech USA, Inc.1$66
Recor Medical Inc2$65
Ultragenyx Pharmaceutical Inc.4$65
Kowa Pharmaceuticals America, Inc.3$64
Amryt Pharma Holdings Ltd3$62
Nevro Corp.3$62
Vifor Pharma, Inc.3$58
Covidien LP1$49
Takeda Pharmaceuticals U.S.A., Inc.2$43
ANI Pharmaceuticals, Inc.2$43
Ascensia Diabetes Care US Inc.1$43
BETA Bionics, Inc.2$40
Antares Pharma, Inc.2$39

How this compares

$3,660,515 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$209,552
Medicare patients
472
Services billed
2,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Lufkin

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →